Síndrome hepatorrenal: fisiopatología, diagnóstico y manejo
DOI:
https://doi.org/10.22516/25007440.83Palavras-chave:
Síndrome hepatorrenal, cirrosis, diagnóstico, tratamientoResumo
El síndrome hepatorrenal es la forma de disfunción renal que complica a los pacientes con enfermedad hepática avanzada o insuficiencia hepática aguda. En él se presentan alteraciones notables en la circulación renal arterial, lo cual conlleva a una elevación progresiva de los niveles de creatinina y ascitis. En la actualidad su esquema de tratamiento farmacológico es limitado, por lo que la mejor opción terapéutica resulta ser el trasplante hepático.
Downloads
Referências
Longo DL, Fauci AS, Kasper DL, Hauster SL, Jamenson JL, Harrison JL. Principios de Medicina Interna. 18.a edición. México, D.F. McGRAW-HILL. 2012. p. 2601.
Toranzo Labrada R, González Castilla R, García Medina J. Síndrome hepatorrenal: diagnóstico y tratamiento. Medisan. 2012;16(5):787.
Higuera-de la Tijera MF et al. Conceptos actuales en síndrome Hepatorrenal. Rev Med Hosp Gen Méx. 2011;74(1):42-9.
Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279-90.
Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. septiembre de 2007;56(9):1310-8.
Muñoz SJ. The hepatorenal syndrome. Med Clin N Am 2008;92:813–837
Ginés P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-54.
De BK, Gangopadhyay S, Dutta D, et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: A randomized controlled trial. World J Gastroenterol. 2009;15:1613-9.
Craig E. Gordon. Hepatorenal Syndrome. HospMedClin. 2012;1:e62-e68.
Fowler C. Management of patients with complications of cirrhosis. Nurse Pract. 2013;38(4):14-21-23.
Egerod Israelsen M, Gluud LL, Krag A. Acute kidney injury and hepatorenal syndrome in cirrhosis. J Gastroenterol Hepatol. febrero de 2015;30(2):236-43.
García Bueya, F. González Mateosb y R. Moreno-Oteroa. Cirrosis hepática. Medicine. 2012;11(11):625-33.
Lefton HB, Rosa A, Cohen M. Diagnosis and epidemiology of cirrhosis. Med Clin North Am. 2009;93(4):787-799, vii.
de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53(4):762-8.
Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744-9.
D’Amico G, García-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-31.
Nagula S, Jain D, Groszmann RJ, García-Tsao G. Histologicalhemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol. 2006;44:111-7.
De Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762-8.
Brinch K, Moller S, Bendtsen F, Becker U, Henriksen JH. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J. Hepatol. 2003;39:24-31.
Gines P, Schrier RW. Renal failure in cirrhosis. N. Engl. J. Med. 2009;361:1279-90.
Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J. Hepatol. 2013; 60:197-209.
Madsen BS, Havelund T, Krag A. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. Adv Ther. 2013;30(7):659-70.
Ruiz-del-Arbol L, Urman J, Fernández J, González M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38(5):1210-8.
Ruiz-del-Arbol L, Urman J, Fernández J, González M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38(5):1210-8.
Mackelaite L, Alsauskas ZC, Ranganna K. Renal failure in patients with cirrhosis. Med Clin North Am. 2009;93(4):855- 869, viii.
Guevara M, Bru C, Ginès P, Fernández-Esparrach G, Sort P, Bataller R, et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology. 1998;28(1):39-44.
Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003;38 Suppl 1:S69-89.
Faber JE, Brody MJ. Afferent renal nerve-dependent hypertension following acute renal artery stenosis in the conscious rat. Circ Res. 1985;57(5):676-88.
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018-26.
Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40(4):802-10.
Hasper D, Jörres A. New insights into the management of hepato-renal syndrome. Liver Int. 2011;31 Suppl 3:27-30.
Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003;38 Suppl 1:S69-89.
Pérez RM. Síndrome hepatorrenal: Enfoque actual. GastrLatinoam. 2006;17:211-217.
Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968-74.
Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-8.
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.
Lenaerts A, Codden T, Meunier J-C, Henry J-P, Ligny G. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology. 2006;44(4):844-9.
Leithead JA, Hayes PC, Ferguson JW. Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction. Aliment Pharmacol Ther. 2014;39(7):699-711.
Francoz C, Durand F. Type-1 hepatorenal syndrome in patients with cirrhosis and infection vs. sepsis-induced acute kidney injury: what matters? J Hepatol. mayo de 2014;60(5):907-9.
Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014;60(5):955-61.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Métricas do artigo | |
|---|---|
| Vistas abstratas | |
| Visualizações da cozinha | |
| Visualizações de PDF | |
| Visualizações em HTML | |
| Outras visualizações | |
